



# Excel with us



Fermion is a subsidiary  
of Orion Corporation

# Fermion in brief

## WHO WE ARE

Fermion, a fully owned subsidiary of Orion Corporation, develops, manufactures, and markets Active Pharmaceutical Ingredients (APIs) under exclusive contracts for New Chemical Entities (NCEs) and for global generic market. Fermion is headquartered in Finland.

## WHAT WE OFFER

We are a fully integrated Contract Development and Manufacturing Organization (CDMO), also serving the global generic API market with end-to-end drug substance services.

## OUR CAPABILITIES

- API Portfolio: 15+ NCEs and 22 generic APIs
- Manufacturing: 2 state of the art API sites and R&D facilities in Finland
- Advanced HPAPI manufacturing capabilities

## QUALITY AND COMPLIANCE

All sites operate under cGMP and meet high standards for safety, sustainability, and regulatory compliance. Regularly inspected by global authorities including the US FDA.

OPERATES  
IN FINLAND WITH

# 400

EMPLOYEES

# 80

R&D AND ANALYTICAL  
DEVELOPMENT  
PROFESSIONALS

# 30%

OF R&D STAFF HAS  
PHD LEVEL EDUCATION

## Locations and facility profiles



### OULU SITE (OEB 3-5)


- Highly potent APIs
- Cytotoxic APIs
- OEB5 micronization

### ESPOO SITE (OEB 3-5)

- Highly potent APIs
- Kilo-scale R&D API unit
- R&D

### HANKO SITE (OEB 3-5)

- Highly potent APIs
- Large volume APIs



### SALO SITE

- Tablet packaging

### TURKU SITE

- Hormone gels & solutions
- Tablets & capsules
- Cytotoxic tablets
- Creams & ointments

### ESPOO SITE

- Tablets & capsules

## CDMO API

Fermion offers full CDMO services from early clinical development to commercial production, with a proven track record in new chemical entity (NCE) development. We've contributed to over 15 NCEs now marketed globally in the USA, EU, Japan, and China.

# 15

CDMO APIS

## Generic API

Fermion supports your generic API needs with over 20 well established commercial products which are registered globally.

# 22

GENERIC APIS

## CMO Drug product

Fermion markets all contract manufacturing services of the Orion Group, including Finished Dosage Form (FDF) manufacturing provided by our parent company Orion. With more than 100 years of pharmaceutical production experience, Orion manufactures a wide range of finished dosage forms such as nonsterile hormonal semi solids, cytotoxic oral solids, tablets, and capsules.

## CDMO API



### CDMO API EXPERTISE FROM CLINICAL TO COMMERCIAL

Fermion supports your API needs from Phase I trials to commercial production.



15 new chemical entities developed with Fermion's support are now marketed globally in the USA, EU, Japan, and China.



Our team includes 55 R&D (30% PhDs) and 25 in analytical development.



Commercial FDA, EMA and CFDI (China) approved API manufacturing sites. Total volume of reactors is 340 m<sup>3</sup>.



Capabilities to manufacture highly potent APIs from 1 to 1,000 kg batch size, including all aspects from chemistry to particle size engineering.

Fermion has a strong position in global market with a number of its generic APIs.

PRODUCT	USA	EUROPE	JAPAN	BRAZIL/KOREA/CHINA
Alprazolam	DMF	CEP	JMF	
Azathioprine	DMF	CEP	JMF	KDMF
Benserazide		CEP		KDMF
Budesonide		CEP		
Buspirone HCl	DMF	CEP		
Carbidopa	DMF	CEP		BDMF, KDMF
Dexmedetomidine	DMF	ASMF	JMF	BDMF, CDMF, KDMF
Diltiazem HCl	DMF	ASMF		
Entacapone	DMF	CEP		KDMF
Fluticasone propionate		CEP		
Formoterol fumarate	DMF	CEP	JMF	CDMF
Hydroxychloroquine sulphate	DMF	CEP	JMF	
Irinotecan HCl	DMF	CEP	JMF	CDMF, KDMF
Levosimendan	DMF	ASMF		
Mercaptopurine	DMF	CEP	JMF	
Methotrexate	DMF	CEP	JMF	BDMF
Methotrexate disodium	DMF	ASMF		
Nadolol	DMF	ASMF	JMF	
Nintedanib	DMF	ASMF		CDMF, KDMF
Quetiapine fumarate	DMF	CEP		
Sodium cromoglicate	DMF	CEP	JMF	CDMF
Tolnaftate	DMF	ASMF		
Toremifene Citrate	DMF	ASMF	JMF	

Products under development: [www.fermion.fi](http://www.fermion.fi)